Search peptides, terms, sources/
Metabolic and incretin

Mazdutide

Not authorised in the UK; approved in China. Peptide that activates glucagon and GLP-1 receptors, studied in phase 3 trials in Chinese adults.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Strong evidence (level 4 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

2 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Mazdutide is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials4 human trials

What is Mazdutide?

Mazdutide is a synthetic peptide that activates both the glucagon receptor and the GLP-1 receptor, studied in phase 3 trials for weight management and type 2 diabetes. It is not authorised in the UK. It is approved in China, and the trials were in Chinese adults only.

Class
Incretin mimetic, Dual glucagon/GLP-1 receptor agonist
Origin
Analogue / modified
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Mazdutide work?

Mazdutide is described in the published literature as a dual agonist that activates the glucagon receptor and the GLP-1 receptor. GLP-1 receptor activation is the mechanism used by licensed GLP-1 medicines such as semaglutide. How the added glucagon activity contributes is a proposed mechanism, not independently confirmed.

The mechanism in more detail

Mazdutide is described in the published literature as a dual agonist: it activates the glucagon receptor (GcgR) and the GLP-1 receptor. GLP-1 receptor activation is the same mechanism used by licensed GLP-1 medicines such as semaglutide, which acts on appetite and on glucose-dependent insulin release.

The added glucagon receptor activity is what separates it from single GLP-1 agonists. This site cites no dedicated receptor-pharmacology paper for mazdutide, so treat the account of how the glucagon part contributes as proposed rather than independently confirmed. It is developed by Eli Lilly and Innovent Biologics (Shirley, Drugs 2025), and the trials below were run by one or the other.

Classification and structure

Names
Mazdutide
Class
Incretin mimetic Dual glucagon/GLP-1 receptor agonist
Origin
Analogue / modified
Structure
A synthetic peptide that acts at the glucagon receptor and the GLP-1 receptor. Exact sequence and modification detail is not given here.
Routes used in the research
Subcutaneous injection in the cited US phase 2 and type 2 diabetes trials, where the abstracts state the route. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Mazdutide has 5 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

5 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
00221

GLORY-1, phase 3 in China Strong

In a 48-week, double-blind, placebo-controlled phase 3 trial of 610 Chinese adults with overweight or obesity (GLORY-1), both mazdutide groups lost about 10% and 13% of body weight by week 32 versus a 0.5% gain on placebo. By week 48 the losses were about 11% and 14%, and about 36% and 50% of the two groups had lost at least 15%, versus 2% on placebo.

Study type
Human trial
Population
610 Chinese adults aged 18 to 75 with BMI 28 or above, or 24 to under 28 with a weight-related condition; phase 3, multicentre, randomised 1:1:1.
Source
1 Ji et al., 2025

Limitation: Sponsor-funded (Innovent Biologics).

Limitations in full

Sponsor-funded (Innovent Biologics). Chinese population only, so results may not carry over to other groups. Abstract read via Europe PMC; full text not read.

GLORY-2, phase 3 in China Strong

In a 60-week, double-blind, placebo-controlled phase 3 trial of 462 randomised Chinese adults with obesity (GLORY-2), mazdutide produced a mean weight change of -16.65% versus -1.50% on placebo (difference -15.15%, 95% CI -17.22 to -13.09). At least 5% weight loss was reached by 84.3% versus 33.1%.

Study type
Human trial
Population
462 randomised Chinese adults with BMI 30 or above, 16.1% with type 2 diabetes, mean age about 34, randomised 2:1; reduced-calorie diet and more physical activity in both groups.
Source
2 Gao et al., 2026

Limitation: Chinese population only, mostly young adults.

Limitations in full

Chinese population only, mostly young adults. The Europe PMC record gives no funding statement, but several authors are Innovent Biologics staff. Abstract read via Europe PMC; full text not read.

US phase 2 trial Moderate

In a 48-week phase 2 trial of 179 US adults with obesity or overweight and no type 2 diabetes, body weight at week 32 changed by -7.3%, -15.6% and -18.1% across the three mazdutide groups versus -0.9% on placebo; further loss was seen by week 48.

Study type
Human trial
Population
179 US adults aged 18 to 75 with BMI 30 or above, or 27 to under 30 with a weight-related condition; 24 centres, double-blind, placebo-controlled.
Source
3 Hsia et al., 2026

Limitation: Phase 2, small, funded by Eli Lilly.

Limitations in full

Phase 2, small, funded by Eli Lilly. The primary endpoint was at 32 weeks. Abstract read via Europe PMC; full text not read.

Phase 3 in type 2 diabetes Moderate

In a phase 3 trial of 320 Chinese adults with type 2 diabetes not controlled by diet and exercise (mazdutide alone versus placebo), HbA1c at week 24 fell by 1.57 and 2.15 percentage points in the two mazdutide groups versus 0.14 on placebo, and weight fell by 5.6% and 7.8% versus 1.3%.

Study type
Human trial
Population
320 Chinese adults with type 2 diabetes (baseline HbA1c 8.24%, BMI 28.2, diabetes for about 1.9 years), randomised 1:1:1; 24 weeks placebo-controlled, followed by 24 weeks of mazdutide.
Source
4 Zhu et al., 2026

Limitation: Chinese population, mazdutide alone, short placebo-controlled period, funded by Innovent Biologics.

Limitations in full

Chinese population, mazdutide alone, short placebo-controlled period, funded by Innovent Biologics. Abstract read via Europe PMC; full text not read.

Approved in China Not graded

A peer-reviewed summary reports that mazdutide was first approved in China in June 2025 for long-term weight management in adults with obesity or overweight, and again in China in September 2025 for blood-sugar control in adults with type 2 diabetes. The article names China only; it does not name the regulator or say mazdutide is approved anywhere else.

Study type
Academic publication
Population
Approval summary; not a trial.
Source
5 Shirley, 2025

Limitation: A secondary summary of regulatory events, not the regulator's own record.

Limitations in full

A secondary summary of regulatory events, not the regulator's own record. Exact approval days and the issuing authority are not stated in the abstract. Full text not read.

What safety findings have been reported?

3 safety findings are recorded for Mazdutide. A short list does not mean a substance is safe; it reflects what has been studied and reported.

GLORY-2 gastrointestinal events

In GLORY-2, vomiting occurred in 53.1% of mazdutide recipients versus 1.3% on placebo, nausea in 46.9% versus 3.2%, and diarrhoea in 39.4% versus 6.5%. Most adverse events were mild to moderate. Stopping treatment because of adverse events happened in 2.9% versus 0%.

Source
2 Gao et al., 2026

GLORY-1 adverse events

In GLORY-1, adverse events were mostly gastrointestinal and mostly mild to moderate. Stopping treatment because of adverse events occurred in 1.5% and 0.5% of the two mazdutide groups versus 1.0% on placebo.

Source
1 Ji et al., 2025

US phase 2 discontinuations

In the US phase 2 trial, the most common adverse events were gastrointestinal and mostly mild to moderate. Stopping treatment because of adverse events was most frequent, at 20%, in the group given the highest level of treatment, mainly because of gastrointestinal problems.

Source
3 Hsia et al., 2026

What is Mazdutide's UK regulatory status?

Marketing authorisation
None identified. Mazdutide does not appear in the MHRA Products database active-substance index (checked 14 November 2026). It is approved in China, per a peer-reviewed summary (Shirley, Drugs 2025).
Prescription status
Not applicable; no licensed UK product was found to classify.
Medicine class
Not a licensed medicine in the UK.
MHRA position
No MHRA-authorised product containing mazdutide was found in the Products database on 14 November 2026. Absence from the index is a search result on that date, not a regulatory decision.
Authorised use
None in the UK. In China: long-term weight management in adults with obesity or overweight, and blood-sugar control in adults with type 2 diabetes.
Research use
Studied in phase 2 and phase 3 clinical trials run by Eli Lilly and by Innovent Biologics.
Other restrictions
None identified beyond the general Human Medicines Regulations 2012 framework for unlicensed medicinal products.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Mazdutide is recorded as not licensed in the UK (checked 14 November 2026).

References

6 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Ji L, Jiang H, Bi Y, et al. (GLORY-1 Investigators) (2025). Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa2411528 · PMID 40421736 · Original ↗
  2. Gao L, Jiang H, Cai H, et al. (GLORY-2 Trial Investigators) (2026). Treatment With Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMAHuman clinical trial, RCT · DOI 10.1001/jama.2026.8142 · PMID 42251595 · Original ↗
  3. Hsia SH, Bays HE, Billings LK, et al. (2026). Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. The Lancet Diabetes & EndocrinologyHuman clinical trial, RCT · DOI 10.1016/S2213-8587(26)00160-9 · PMID 42628555 · Original ↗
  4. Zhu D, Zhao J, Cai H, et al. (2026). Mazdutide versus placebo in Chinese adults with type 2 diabetes. NatureHuman clinical trial, RCT · DOI 10.1038/s41586-025-10026-w · PMID 41407859 · Original ↗
  5. Shirley M (2025). Mazdutide: First Approval. DrugsNarrative review · DOI 10.1007/s40265-025-02249-y · PMID 41028652 · Original ↗
  6. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about Mazdutide

What is Mazdutide?

Mazdutide is a synthetic peptide that activates both the glucagon receptor and the GLP-1 receptor, studied in phase 3 trials for weight management and type 2 diabetes. It is not authorised in the UK. It is approved in China, and the trials were in Chinese adults only. Read what it is.

Is Mazdutide licensed in the UK?

PeptGuru records Mazdutide's UK status as: Not licensed in the UK. None identified. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Mazdutide show?

PeptGuru records 5 research findings for Mazdutide: 4 from human trials and 1 from a regulatory or other record. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Mazdutide?

3 safety findings are recorded, including: GLORY-2 gastrointestinal events; GLORY-1 adverse events; US phase 2 discontinuations. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Mazdutide?

All 6 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · Mazdutide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • Survodutide

    Investigational peptide that activates glucagon and GLP-1 receptors. Not authorised in the UK. Studied in phase 3 trials, all sponsor-funded.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • RetatrutideLY3437943

    Investigational triple GIP, GLP-1 and glucagon receptor agonist studied for weight management. Not licensed in the UK; studied in a Phase 2 trial.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK

Compare Mazdutide with Survodutide

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.